Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K060354
    Manufacturer
    Date Cleared
    2006-07-28

    (165 days)

    Product Code
    Regulation Number
    862.3170
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Device Name :

    ACRO BIOTECH LLC RAPID BENZODIAZEPINE URINE TEST, CATALOG BZD001000

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    Acro Rapid Benzodiazepine Urine Test is a lateral flow, rapid immunoassay for the qualitative Acro Rapid Oxazepam in human urine at a cutoff of 300 ng/mL. The test is used to obtain a visual, qualitative result and is intended for laboratory use only. This assay provides only a preliminary result. Clinical consideration and professional judgment must be applied to a drug test result, particularly in evaluating a preliminary positive result. In mast be applied to a more specific al result, a more specific alternate chemical method is needed. Gas Chromatography/ Mass Spectroscopy (GC/MS) analysis is preferred.

    Device Description

    Not Found

    AI/ML Overview

    The provided text is related to a 510(k) premarket notification for a medical device called "Acro Rapid Benzodiazepine Urine Test." This seems to be an in-vitro diagnostic device.

    Unfortunately, the provided text does not contain any information about acceptance criteria, detailed study designs, sample sizes for training/test sets, ground truth establishment, expert qualifications, adjudication methods, or MRMC studies.

    The document is a letter from the FDA confirming the substantial equivalence of the device to legally marketed predicate devices, allowing it to be marketed. It also includes the "Indications for Use" for the device, which states:

    Device Name: Acro Rapid Benzodiazepine Urine Test
    Indications for Use: Acro Rapid Benzodiazepine Urine Test is a lateral flow, rapid immunoassay for the qualitative detection of Oxazepam in human urine at a cutoff of 300 ng/mL. The test is used to obtain a visual, qualitative result and is intended for laboratory use only.

    The letter explicitly states that this assay provides only a preliminary result and that a more specific alternate chemical method (like Gas Chromatography/ Mass Spectroscopy (GC/MS) analysis) is needed to confirm a preliminary positive result. This implies that the device itself is not providing a definitive diagnostic outcome, but rather a screening result.

    Therefore, I cannot fulfill your request for the specific details about acceptance criteria and the study proving the device meets them based on the provided text. This information would typically be found in the 510(k) submission summary or detailed study reports, which are not included in this extract.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1